europass Curriculum vitae

PERSONAL INFORMATION

Massimo Di Maio

WORK EXPERIENCE

September 2012–Present

Associate Professor of Medical Oncology

University of Turin, Department of Oncology, (Italy)

October 2006–September 2008

Physician assistant, Clinical trials Unit

National Cancer Institute , (Italy)

September 2005–August 2008

Physician assistant, Medical Oncology

“N. Giannettasio” Hospital, Rossano (CS), (Italy)

EDUCATION AND TRAINING

October 1999–October 2004

Specialty School in Oncology

University of Naples “Federico II”, (Italy)

October 1993–October 1999

Degree cum laude in Medicine & Surgery

University of Naples “Federico II”, (Italy)

ADDITIONAL INFORMATION

Expertise

Publications

Other 2004, 2005, 2006. Winner of an AIRC (Associazione Italiana per la Ricerca sul Cancro) / FIRC fellowship, with a project on “Determinants of quality of life in patients with advanced NSCLC” (frequency at Clinical trials Unit, National Cancer Institute, Napoli, Italy).

2010-2012. Winner of an AIRC grant “My first AIRC grant” with a project on: “Endocrine predictive factors of the effect of aromatase inhibitors as adjuvant treatment of breast cancer.”

2009 – 2013. National Coordinator of Young Oncologists Committee of Associazione Italiana di Oncologia Medica (Italian Society of Medical Oncology, AIOM).

2013 – present: Member of the National Council of Associazione Italiana di Oncologia Medica (Italian Society of Medical Oncology, AIOM).

Scientific publications

h-index as of November 2014 (source: Web of Science Citation Report): 25

139 Normanno N, Rossi A, Morabito A, Signoriello S, Bevilacqua S, Di Maio M, Costanzo R, De Luca A, Montanino A, Gridelli C, Rocco G, Perrone F, Gallo C. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. Lung Cancer. 2014 May 14. [Epub ahead of print]

138 Pignata S, Di Maio M, Gallo C, Perrone F. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - Authors' reply. Lancet Oncol. 2014 Jun;15(7):e250-1.

137 Di Maio M, De Marinis F, Hirsch FR, Gridelli C. Diagnostic and therapeutic issues for patients with advanced non?small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (Review). Int J Oncol. 2014 May 21. [Epub ahead of print]

136 Morabito A, Carillio G, Daniele G, Piccirillo MC, Montanino A, Costanzo R, Sandomenico C, Giordano P, Normanno N, Perrone F, Rocco G, Di Maio M. Treatment of small cell lung cancer. Crit Rev Oncol Hematol. 2014 Apr 2. [Epub ahead of print] Review.

135 Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi

L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014 Apr;15(4):396-405.

134 Cohen MJ, Levy I, Barak O, Bloom AI, Fernández-Ruiz M, Di Maio M, Perrone F, Poon RT, Shouval D, Yau T, Shibolet O. Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver Int. 2014 Feb 10. [Epub ahead of print]

133 Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2013 Dec 27. [Epub ahead of print] Review.

132 Gridelli C, Rossi A, Di Maio M, Leo S, Filipazzi V, Favaretto AG, Burgio MA, Cinieri S, Bianco R, Ciardiello F, Cavanna L, Bordonaro R, Costanzo R, Sandomenico C, Gallo C, Perrone F, Morabito A. Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2014 Mar;15(2):166-70.

131 Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E. Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. Crit Rev Oncol Hematol. 2013 Dec 1. pii: S1040-8428(13)00252-7. [Epub ahead of print]

130 La Verde N, Moretti A, Farina G, Dazzani MC, Gamucci T, Borgonovo K, Botta M, Salesi N, Zuradelli M, Pavese I, Barbieri E, Cretella E, Saladino T, Varese P, Traverso ES, Addamo G, Ciccarese M, Rispoli AI, Pellegrino A, Mentuccia L, Girelli S, Piva S, Di Maio M. Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. Future Oncol. 2013 Dec;9(12):1841-8.

129 Di Maio M, Morabito A, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Sandomenico C, Montanino A, Rocco G, Perrone F. Combining anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better. Curr Pharm Des. 2013 Nov 5. [Epub ahead of print]

128 Costanzo R, Montanino A, Di Maio M, Piccirillo MC, Sandomenico C, Giordano P, Daniele G, Franco R, Perrone F, Rocco G, Normanno N, Morabito A. Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Rev Anticancer Ther. 2013 Oct;13(10):1207-18.

127 Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA, Evans WK. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). Lung Cancer. 2013 Oct;82(1):115-20.

126 Morabito A, Gebbia V, Di Maio M, Cinieri S, Viganò MG, Bianco R, Barbera S, Cavanna L, De Marinis F, Montesarchio V, Costanzo R, Sandomenico C, Montanino A, Mancuso G, Russo P, Nacci A, Giordano P, Daniele G, Piccirillo MC, Rocco G, Gridelli C, Gallo C, Perrone F. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study. Lung Cancer. 2013 Jul;81(1):77-83.

125 Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Lunardi G, Venturini M; AIOM Working Group "Interaction with Regional Sections" (2009-2011). Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). Tumori. 2013 Jan-Feb;99(1):35-8.

124 Rocco G, Gatani T, Di Maio M, Meoli I, La Rocca A, Martucci N, La Manna C, Stefanelli F. The impact of decreasing cutoff values for maximal oxygen consumption (VO(2)max) in the decision-making process for candidates to lung cancer surgery. J Thorac Dis. 2013 Feb;5(1):12-8.

123 Di Maio M, Costanzo R, Giordano P, Piccirillo MC, Sandomenico C, Montanino A, Carillio G, Muto P, Jones DR, Daniele G, Perrone F, Rocco G, Morabito A. Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer. Anticancer Agents Med Chem. 2013 Jul

1;13(6):844-51.

122 Di Maio M, Bria E, Banna GL, Puglisi F, Garassino MC, Lorusso D, Perrone F. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. Anticancer Drugs. 2013 Feb;24(2):99-111.

121 Hotta K, Suzuki E, Di Maio M, Chiodini P, Fujiwara Y, Takigawa N, Ichihara E, Reck M, Manegold C, Pilz L, Hisamoto-Sato A, Tabata M, Tanimoto M, Shepherd FA, Kiura K. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. 2013 Jan;79(1):20-6.

120 Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C; TORCH Investigators. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Dec;7(12):1830-44.

119 Rossi A, Martelli O, Di Maio M. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev. 2013 Aug;39(5):498-506.

118 Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R, Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F, Mancuso G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G, Piccirillo MC, Di Maio M, Morabito A, Perrone F. First-line erlotinib followed by second-line cisplatin gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012 Aug 20;30(24):3002-11.

117 Signoriello S, Annunziata A, Lama N, Signoriello G, Chiodini P, De Sio I, Daniele B, Di Costanzo GG, Calise F, Olivieri G, Castaldo V, Lanzetta R, Piai G, Marone G, Visconti M, Fusco M, Di Maio M, Perrone F, Gallo C, Gaeta GB. Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in

real-world patients. ScientificWorldJournal. 2012;2012:564706. doi: 10.1100/2012/564706. Epub 2012 May 3.

116 Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012 May 10;30(14):1692-8.

115 Giuliani F, Di Maio M, Colucci G, Perrone F. Conventional chemotherapy of advanced pancreatic cancer. Curr Drug Targets. 2012 Jun;13(6):795-801.

114 Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P. Role of sistemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled

trials. Oncol Rep. 2012 Jun;27(6):1849-56.

113 Nuzzo F, Gallo C, Lastoria S, Di Maio M, Piccirillo MC, Gravina A, Landi G, Rossi E, Pacilio C, Labonia V, Di Rella F, Bartiromo A, Buonfanti G, De Feo G, Esposito G, D'Aniello R, Maiolino P, Signoriello S, De Maio E, Tinessa V, Colantuoni G, De Laurentiis M, D'Aiuto M, Di Bonito M, Botti G, Giordano P, Daniele G, Morabito A, Normanno N, de Matteis A, Perrone F. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. Ann Oncol. 2012 Aug;23(8):2027-33.

112 Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel. Lung Cancer. 2012 Jul;77(1):116-20.

111 Carillio G, Montanino A, Costanzo R, Sandomenico C, Piccirillo MC, Di Maio M, Daniele G, Giordano P, Bryce J, Normanno N, Rocco G, Perrone F, Morabito A. Cetuximab in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2012 Feb;12(2):163-75.

110 Di Maio M, Signoriello S, Morabito A, Rossi A, Maione P, Piantedosi F, Bilancia D, Cigolari S, Barbera S, Gebbia V, Daniele B, Robbiati SF, Illiano A, Ceribelli A, Carrozza F, Favaretto A, Piazza E, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Sandomenico C, Rocco G, Gallo C, Perrone F, Gridelli C. Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. Lung Cancer. 2012 Jun;76(3):457-64.

109 Gridelli C, de Marinis F, Di Maio M, Ardizzoni A, Belani CP, Cappuzzo F, Ciardiello F, Fidias P, Paz-Ares L, Perrone F, Pirker R, De Petris L, Stahel R. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of

thoracic oncology. Lung Cancer. 2012 Jun;76(3):269-79.

108 Sandomenico C, Costanzo R, Carillio G, Piccirillo MC, Montanino A, Di Maio M, Rocco G, Normanno N, Perrone F, Morabito A. Bevacizumab in non small cell lung cancer: development, current status and issues. Curr Med Chem. 2012;19(7):961-71.

107 Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto A, Isa L, Barbera S, Gamucci T, Ceribelli A, Filipazzi V, Maione P, Rossi A, Barletta E, Signoriello S, De Maio E, Piccirillo MC, Di Maio M, Rocco G, Vecchione A, Perrone F; G-STEP Investigators. Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. J Thorac Oncol. 2012 Jan;7(1):233-42.

106 Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Venturini M; AIOM Working Group "Interactions with Regional Sections" (2009-2011). Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). Tumori. 2011 Jul-Aug;97(4):442-8.

105 Marchetti C, Pisano C, Mangili G, Lorusso D, Panici PB, Silvestro G, Candiani M, Greggi S, Perniola G, Di Maio M, Pignata S. Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: a multicenter retrospective study. Oncology. 2011;81(2):104-12.

104 Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer:the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628-35.

103 Di Maio M. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer. Expert Opin Biol Ther. 2011 Sep;11(9):1131-3.

102 de Bellis M, Accardo R, Di Maio M, La Manna C, Rossi GB, Pace MC, Romano V, Rocco G. Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery? Eur J Cardiothorac Surg. 2011Oct;40(4):912-6

101 Costanzo R, Piccirillo MC, Sandomenico C, Carillio G, Montanino A, Daniele G, Giordano P, Bryce J, De Feo G, Di Maio M, Rocco G, Normanno N, Perrone F, Morabito A. Gefitinib in non small cell lung cancer. J Biomed Biotechnol. 2011;2011:815269. Epub 2011 May 23.

100 Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M, Garassino M, Maione P, Martelli O, Vavalà T, Bria E. Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res. 2011 May 6;30:50.

99 de Marinis F, Rossi A, Di Maio M, Ricciardi S, Gridelli C. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer. 2011 Jul;73(1):1-10.

98 Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M; AIOM Working Group Interaction with

Regional Sections (2007-2009). Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). Tumori. 2010 Nov-Dec;96(6):1010-5.

97 Daniele G, Giordano P, De Luca A, Piccirillo MC, Di Maio M, Del Giudice A, De Feo G, Bryce J, Lamura L, Vecchione A, Normanno N, Perrone F. Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. Expert Rev Anticancer Ther. 2011 Feb;11(2):299-307.

96 Nuzzo F, Morabito A, Gravina A, Di Rella F, Landi G, Pacilio C, Labonia V, Rossi E, De Maio E, Piccirillo MC, D'Aiuto G, Thomas R, Rinaldo M, Botti G, Di Bonito M, Di Maio M, Gallo C, Perrone F, de Matteis A. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or

metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer. 2011 Feb 16;11:75.

95 De Vita F, Orditura M, Martinelli E, Vecchione L, Innocenti R, Sileni VC, Pinto C, Di Maio M, Farella A, Troiani T, Morgillo F, Napolitano V, Ancona E, Di Martino N, Ruol A, Galizia G, Del Genio A, Ciardiello F. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer. 2011 Feb

1;104(3):427-32.

94 Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications

for clinical practice and open issues. Lung Cancer. 2011 Apr;72(1):3-8.

93 Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer. 2011 Mar;71(3):249-57.

92 Gridelli C, Morgillo F, Favaretto A, de Marinis F, Chella A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M, Pasello G, Ricciardi S, Maione P, Di Maio M, Ciardiello F. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase

II study. Ann Oncol. 2011 Jul;22(7):1528-34.

91 Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E; on behalf of ISA Co-Authors. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer. 2011 Jul;73(1):78-88. Epub 2010 Dec 8.

90 Di Maio M, Morabito A, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Riccardi MG, Rocco G, Normanno N, Perrone F. New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. Expert Opin Investig Drugs. 2010 Dec;19(12):1503-14. Epub 2010 Nov 4.

89 Morabito A, Piccirillo MC, Costanzo R, Sandomenico C, Carillio G, Daniele G, Giordano P, Bryce J, Carotenuto P, La Rocca A, Di Maio M, Normanno N, Rocco G, Perrone F. Vandetanib: An overview of its clinical development in NSCLC and other

tumors. Drugs Today (Barc). 2010 Sep;46(9):683-98.

88 Fujiwara Y, Hotta K, Di Maio M, Kiura K, Takigawa N, Tabata M, Tanimoto M. Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. Ann Oncol. 2011 Feb;22(2):376-82.

87 De Feo G, Signoriello S, Bryce JC, Del Giudice A, Canzanella G, Crudele F, Romano F, de Matteis G, Florio M, Falasconi F, Savio A, Giordano P, Daniele G, Iaccarino M, Piccirillo MC, Di Maio M, Morabito A, Gallo C, Perrone F. Time spent for activation of non-profit studies in oncology in Italy. PLoS One. 2010 Jul

29;5(7):e11864.

86 Esposito I, de Bellis M, de Leone A, Rossi GB, Selvaggi F, Di Maio M, Musto D, Tracey MC, Marone P, Esposito P, Tempesta A, Riegler G. Endoscopic surveillance for hereditary non-polyposis colorectal cancer (HNPCC) family members in a Southern Italian region. Dig Liver Dis. 2010 Oct;42(10):698-703.

85 Piccirillo MC, Daniele G, Di Maio M, Bryce J, De Feo G, Del Giudice A, Perrone F, Morabito A. Vinorelbine for non-small cell lung cancer. Expert Opin Drug Saf. 2010 Mar 30. [Epub ahead of print]

84 Colucci G, La bianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F;

Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin

compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010 Apr 1;28(10):1645-51. Epub 2010 Mar 1.

83 Rossi A, Garassino MC, Cinquini M, Sburlati P, Di Maio M, Farina G, Gridelli C, Torri V. Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2010 Feb 24. [Epub ahead of print]

82 Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 2010 Feb 11. [Epub ahead of print]

81 Gridelli C, Di Maio M. The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial. Expert Opin Pharmacother. 2010 Feb;11(2):321-4.

80 Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a

prognostic score from individual data of nine randomised trials. Eur J Cancer. 2010 Mar;46(4):735-43.

79 Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd FA, De Petris L, Di Maio M, de Marinis F. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an

International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 2009 Dec 23.

78 Di Maio M, Gallo C, De Maio E, Morabito A, Piccirillo MC, Gridelli C, Perrone F. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer. 2010 Feb;67(2):127-35.

77 Di Maio M, Daniele B, Perrone F. Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. Nat Rev Clin Oncol. 2009 Sep;6(9):505-6.

76 Morabito A, Piccirillo MC, De Maio E, Di Maio M, Perrone F. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased? J Clin Oncol. 2009 Sep 20;27(27):e123; author reply e124-5.

75 Bria E, Cuppone F, Di Maio M. Cetuximab for metastatic colorectal cancer. N Engl J Med. 2009 Jul 2;361(1):95-6; author reply 96-7.

74 Daniele B, Di Maio M. Target therapy for hepatocellular carcinoma: is sorafenib for everybody? J Clin Gastroenterol. 2009 May-Jun;43(5):389-90.

73 Di Maio M, Perrone F. Registrative trials of antiemetic drugs: arrival or starting point? Lancet Oncol. 2009 Jun;10(6):533-4.

72 Bria E, Di Maio M, Carlini P, Cuppone F, Giannarelli D, Cognetti F, Micella M. Targeting targeted agents: open issues for clinical trial design. J Exp Clin Cancer Res. 2009 May 22;28:66.

71 Loupakis F, Di Maio M, Falcone A. Chemotherapy and immunotherapy in metastatic colorectal cancer. N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6.

70 Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, De Maio E, Di Maio M, Piccirillo MC, De Feo G, D'Aiuto G, Botti G, Chiodini P, Gallo C, Perrone F, de Matteis A. Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal

Patients With Early Breast Cancer: The HOBOE Trial. J Clin Oncol. 2009 Apr 20. [Epub ahead of print]

69 Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Viganò MG, Verusio C, Bollina R, Mattioli R, Valerio MR, Valmadre G, Maione P, Rossi A, Cascone T, Morgillo F, Di Maio M, Piccirillo MC, Gallo C, Perrone F, Ciardiello F. Cetuximab

and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer. 2009 Apr 18. [Epub ahead of print]

68 Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth

factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009 Apr;14(4):378-90. Epub 2009 Apr 6.

67 Maione P, Rossi A, Di Maio M, Gridelli C. Tumor-related leucocytosis and chemotherapy-induced neutropenia: Linked or independent prognostic factors for advanced non-small cell lung cancer?. Lung Cancer. 2009 Mar 26. [Epub ahead of

print]

66 Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line

treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2009 Apr 10;27(11):1836-43. Epub 2009 Mar 9.

65 Pisano C, Morabito A, Sorio R, Breda E, Lauria R, Gebbia V, Scaltriti L, Scalone S, Zagonel V, Greggi S, Beneduce G, Losito S, Gallo C, Di Maio M, Forestieri V, Pignata S. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian

trial in ovarian cancer (MITO-6) trial. Cancer Chemother Pharmacol. 2009 Mar 6. [Epub ahead of print]

64 Di Maio M, Perrone F. Palonosetron: more than just another option?. Lancet Oncol. 2009 Feb;10(2):100-1.

63 Di Maio M, Daniele B, Gallo C, Perrone F. Re: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008

62 Abruzzese E, Iuliano F, Trawinska MM, Di Maio M. 153Sm: its use in multiple myeloma and report of a clinical experience. Expert Opin Investig Drugs. 2008 Sep;17(9):1379-87.

61 Gebbia V, Gridelli C, Verusio C, Frontini L, Aitini E, Daniele B, Gamucci T, Mancuso G, Di Maio M, Gallo C, Perrone F, Morabito A. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients The DISTAL-2 randomized trial. Lung Cancer. 2008 Jul 14. [Epub ahead of print]

60 Di Maio M, Daniele B, Pignata S, Gallo C, De Maio E, Morabito A, Piccirillo MC, Perrone F. Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol. 2008 Mar 21;14(11):1682-9. Review.

59 Di Maio M, Gallo C, Perrone F. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy] Tumori. 2008 Mar-Apr;94(2):suppl 14-22.

58 Gridelli C, Rossi A, Morgillo F, Bareschino MA, Maione P, Di Maio M, Ciardiello F. A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. Clin Lung Cancer. 2007 Nov;8(9):568-71.

57 Di Maio M, Bria E, Rossi A, Perrone F. Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter? Ann Oncol. 2008 Feb;19(2):402-3.

56 Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatol Res. 2007 Sep;37 Suppl 2:S206-9.

55 Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F; GECO investigators. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol. 2007 Jun;8(6):500-12.

54 Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer 2007; 96(11):1639-43.

54 Pizzi C, Di Maio M, Daniele S, Mastranzo P, Spagnoletti I, Limite G, Pettinato G, Monticelli A, Cocozza S, Contegiacomo A. Triplet repeat instability correlates with dinucleotide instability in primary breast cancer. Oncol Rep. 2007 Jan;17(1):193-9.

53 Di Maio M, Perrone F, Chiodini P, Gallo C, Camps C, Schuette W, Quoix E, Tsai CM, Gridelli C. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 1377-1382.

52 Gridelli C, Aapro MS, Barni S, Beretta GD, Colucci G, Daniele B, Del Mastro L, Di Maio M, De Petris L, Perrone F, Thatcher N, De Marinis F. Role of colony stimulating factors in solid tumours: Results of an experts panel. Crit Rev Oncol Hematol 2007 Jul;63(1):53-64.

51 Di Maio M, De Maio E, Morabito A, D'Aniello R, De Feo G, Gallo C, Perrone F. Hormonal treatment of human hepatocellular carcinoma. Ann NY Acad Science 2006; 1089:252-261

50 Bria E, Di Maio M, Cuppone F, Nisticò C, Cognetti F, Giannarelli D. Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice? (Correspondence) Journal of Clinical Oncology 2007; 25: 605-606

49 Picone GM, Pizzi C, Quartuccio A, Scognamiglio G, Tauchmanova L, Di Maio M, Cifarelli P, Contegiacomo A. Incidence and pathological characteristics of prostate cancer in Italy: A contribution to the screening debate. Cancer Detection and Prevention 2006; 30: 455-458.

48 Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer. 2006 Aug 29; [Epub ahead of print]

47 Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G,

Annunziata A, Perrone F; MITO Investigators. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer 2006; 6: 202.

46 Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11: 753-764.

45 Gallo C, De Maio E, Di Maio M, Signoriello G, Daniele B, Pignata S, Annunziata A, Perrone F; CLIP Investigators. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. BMC Cancer 2006; 6:196

44 Bria E, Di Maio M, Nistico C, Cuppone F, Terzoli E, Cognetti F, Giannarelli D. Factorial design for randomized clinical trials. Ann Oncol. 2006; 17: 1607-1608.

43 Pignata S, Pisano C, Di Maio M, Iodice F, Casella G, Laurelli G, Greggi S, Iaffaioli RV. Medical treatment of resistant or recurrent epithelial ovarian cancer. Ann Oncol. 2006;17 Suppl 7:vii49-vii50.

42 Morabito A, Di Maio M, De Maio E, Normanno N, Perrone F. Methodology of clinical trials with new molecular-targeted agents: where do we stand?

Ann Oncol 2006;17 Suppl 7: vii128- vii131.

41 M Di Maio, C Gridelli, C Gallo, F Perrone. Viewpoint: Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy? Nature Clinical Practice Oncology 2006, 3: 2-3

40 S Pignata, C Gallo, B Daniele, S Elba, A Giorgio, G Capuano, LE Adinolfi, I De Sio, F Izzo, F Farinati, C Del Naja, M Stanzione, F Castiglione, G Marone, O Cuomo, M Felder, GB Gaeta, E De Maio, M Di Maio, G Signoriello, F Perrone on behalf of the CLIP Investigators. Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly.

A study of the Cancer of the Liver Italian Program (CLIP). Crit Rev Oncol Hematol 2006; 59: 243-249

39 S Pignata, S De Placido, R Biamonte, G Scambia, G Di Vagno, G Colucci, A Febbraro, A Vernaglia Lombardi, L Manzione, M Nardi, S Danese, MR Valerio, G Gasparini, M Di Maio, C Pisano, F Perrone. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006; 6:5.

38 M Di Maio, C Pisano, R Tambaro, S Greggi, G Casella, G Laurelli, R Formato, RV Iaffaioli, F Perrone, S Pignata. The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. Frontiers in Bioscience 2006 May 1; 11: 1585-1590.

37 D Califano, S Losito, C Pisano, G Santelli, S Greggi, F Iodice, G Di Vagno, G Silvestro, R Tambaro, R Formato, RV Iaffaioli, M Di Maio, S Pignata. The significance of erb-B2 immunostaining in cervical cancer Frontiers in Bioscience 2006 September 1; 11: 2071-2076.

36 M Di Maio, C Gridelli, C Gallo, F Shepherd, FV Piantedosi, S Cigolari, L Manzione, A Illiano, S Barbera, SF Robbiati, L Frontini, E Piazza, GP Ianniello, E Veltri, F Castiglione, F Rosetti, V Gebbia, L Seymour, P Chiodini, F Perrone. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncology, 2005, Sep;6(9):669-77.

35 Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.

Anticancer Res. 2005 Sep-Oct;25(5):3501-5.

34 N Normanno, M Di Maio, E De Maio, A De Luca, A de Matteis, A Giordano, F Perrone on behalf of the NCI- Naples Breast Cancer Group. Invited Review: Mechanisms of endocrine-resistance and novel therapeutic strategies in breast cancer. Endocrine-related Cancer, 2005 Dec;12(4):721-47.

33 C Gridelli, P Maione, A Rossi, M Di Maio, F Perrone. Chemotherapy of stage I to III non-small-cell lung cancer in elderly patients. 2005 ASCO annual meeting Educational book (supplement of J Clin Oncol), pag.611-617

32 C Gridelli, M Aapro, A Ardizzoni, L Balducci, F De Marinis, K Kelly, T Le Chevalier, C Manegold, F Perrone, R Rosell, F Shepherd, L De Petris, M Di Maio, C Langer. Treatment of advanced non-small-cell lung cancer in the elderly: results of an International Expert Panel. Journal of Clinical Oncology 2005, 23(13): 3125-3137

31 De Maio E, Gravina A, Pacilio C, Amabile G, Labonia V, Landi G, Nuzzo F, Rossi E, D'Aiuto G, Capasso I, Rinaldo M, Morrica B, Elmo M, Di Maio M, Perrone F, de Matteis A. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer. 2005 Mar 24;5(1):30

30 M Di Maio, C Gridelli, N Normanno, F Perrone, F Ciardiello. Trying to compose the puzzle with all

the pieces: Epidermal Growth Factor Receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Cell Physiol 2005 Dec;205(3):355-63.

29 F Perrone, M Di Maio, A Budillon, N Normanno. Targeted therapies and non small cell lung cancer : methodological and conceptual challenge for clinical trials. Curr Opin Oncol 2005 Mar;17(2):123-9.

28 S Pignata, F Perrone , M Di Maio, C Gallo , S De Placido on behalf of the MITO Investigators. Reply to 136-04 (letter). Journal of Clinical Oncology, 2005 Apr 1;23(10):2436-7

27 C Gridelli, C Gallo, M Di Maio, E Barletta, A Illiano, P Maione, S Salvagni, FV Piantedosi, G Palazzolo, O Caffo, A Ceribelli, A Falcone, P Mazzanti, L Brancaccio, MA Capuano, L Isa, S Barbera, F Perrone on behalf of the DISTAL (Docetaxel In Second-line Treatment of Advanced Lung cancer) Investigators. A Randomized clinical trial of two docetaxel regimens (weekly vs 3-week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. British Journal of Cancer 91(12):1996-2004, 2004.

26 Perrone F, Di Maio M, Gallo C, Gridelli C on behalf of the MILES Investigators, Outcome of PS2 patients in the MILES study. Journal of Clinical Oncology (letter) 2004 Dec 15;22(24):5018-20

25 Tambaro R, Scambia G, Di Maio M, Pisano C, Barletta E, Iaffaioli VR, Pignata S. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Crit Rev Oncol Hematol. 2004 Oct;52(1):33-44.

24 De Luca A, Grassi M, Maiello MR, Di Maio M, Mancino M, De Maio E, Gridelli C, Perrone F, Normanno N. Does the sequence of gemcitabine and vinorelbine affect the efficacy in non-small cell lung cancer? Anticancer Research 24: 2985 – 2990, 2004

23 Pisano C, Tambaro R, Di Maio M, Formato R, Iaffaioli VR, Pignata S. Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer. Arch Dermatol Res. 2004 Aug;296(3):141-2. Epub 2004 Jul 20.

22 Ottaiano A, Mollo E, Di Lorenzo G, Pisano C, Di Maio M, Barletta E, Pensabene M, Segati R, Bullian P, Nasti G, Bryce J, Scala S, Castello G, Ascierto PA. Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. Cancer Immunol Immunother. 2004 Jul 3 [Epub ahead of print]

21 M Di Maio, C Gridelli, C Gallo, L Manzione, L Brancaccio, S Barbera, SF Robbiati, GP Ianniello, F Ferraù, E Piazza, L Frontini, F Rosetti, F Carrozza, A Bearz, M Spatafora, V Adamo, L Isa, RV Iaffaioli, E Di Salvo, F Perrone. Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. British Journal of Cancer 2004, 90(12): 2288-2296

20 Normanno N, Di Maio M, Perrone F, Campiglio M. Molecular markers to predict response to gefitinib: EGFR, Erb-B2, or more? Journal of Clinical Oncology 2004, 22(10): 2035-36 (letter)

19 Spagnoletti I, Pizzi C, Galietta A, Di Maio M, Mastranzo P, Daniele S, Limite G, Pettinato G, Contegiacomo A. Loss of hMSH2 expression in primary breast cancer with p53 alterations. Oncology reports, 11(4): 845-851

18 C Gridelli, A Ardizzoni, T LeChevalier, C Manegold, F Perrone, N Thatcher, N van Zandwijk, M Di Maio, O Martelli, F De Marinis. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Annals of Oncology 15: 419-426, 2004.

17 M Di Maio, F Perrone, C Gallo, RV Iaffaioli, L Manzione, FV Piantedosi, S Cigolari, A Illiano, S Barbera, SF Robbiati, E Piazza, GP Ianniello, L Frontini, E Veltri, F Castiglione, F Rosetti, E De Maio, P Maione, C Gridelli. Supportive care in patients with advanced non-small-cell lung cancer. British Journal of Cancer 89: 1013-1021, 2003.

16 M Di Maio, F Perrone. Quality of Life in elderly patients with cancer. Health and Quality of Life Outcomes 1:44, 2003

15 R Tambaro, S Greggi, RV Iaffaioli, A Rossi, C Pisano, L Manzione, E Ferrari, M Di Maio, F Iodice, G Casella, G Laurelli, S Pignata. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. Annals of Oncology, 14: 1406-1411, 2003

14 A Ottaiano, R Tambaro, S Greggi, R Prato, M Di Maio, G Esposito, F Scala, E Barletta, S Losito, R De Vivo, RV Iaffaioli, S Pignata. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Research, 23: 3465-3468, 2003

13 C Gallo, M Di Maio. Quality of life assessment: cancer in the elderly. Tumori 2(1): S61 – S62, 2003.

12 E. Rossi, F. Perrone, V Labonia, G Landi, F Nuzzo, G Amabile, C Gridelli, M Di Maio, G D'Aiuto, A de Matteis. Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase II study. Oncology , 64: 479-480, 2003.

11 F.Perrone, M.Di Maio, E. De Maio, P.Maione, A.Ottaiano, M.Pensabene, G.Di Lorenzo, A.Vernaglia Lombardi, G.Signoriello, C.Gallo. Statistical design in phase II clinical trials and their application in

breast cancer. Lancet Oncology, 4:305–11, 2002.

10 Perrone F, M. Di Maio. Elderly cancer patients: our future? Clinica Terapeutica 153(3):159-60, 2002

9 C.Pizzi, L.Panico, L.De Marchis, P.Mastranzo, M.Di Maio, C D'Amico, G Limite, G Pettinato, S Cocozza, A R Bianco and A Contegiacomo. P53 expression is decreased in primary breast carcinomas with microsatelite instability. Breast Cancer Research and Treatment 73(3):257-66, 2002.

8 M. Di Maio, E. De Maio, F. Perrone, S. Pignata and B. Daniele. Hepatocellular carcinoma: systemic treatments. Journal of Clinical Gastroenterology 35(5 suppl 2)- S109- 114, 2002

7 C.Gridelli, A.Rossi, E.Barletta, N.Panza, L.Brancaccio, R.Cioffi, T.Pedicini, G.P.Ianniello, E.Piazza, N.Rossi, R.V.Iaffaioli, P.Maione, M. Di Maio, C.Gallo, F.Perrone. Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. Lung Cancer ; 36(3):327-32, 2002

6 Pignata S, Di Maio M, Ottaiano A, De Maio E, Barletta E, Pisano C, Tambaro R.Single agents or combination chemotherapy for advanced ovarian carcinoma in elderly patients: pro single agents. Tumori 88(1 Suppl 1):S117-9, 2002.

5 Ottaiano A, Di Maio M, Tambaro R, Bruni GS, Barletta E, Botti G and Iaffaioli VR. Bladder cancer in a patient with widespread psoriasis treated by topical coal-tar application. BJU International 89 (6cr), 634, 2002

4 Perrone F, Gallo C, Daniele B, Gaeta GB, Izzo F, Capuano G, Adinolfi LE, Mazzanti R, Farinati F, Elba S, Piai G, Calandra M, Stanzione M, Mattera D, Aiello A, Sio ID, Castiglione F, Russo M, Persico M, Felder M, Manghisi OG, De Maio E, M Di Maio, Pignata S. Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial. Current Pharmaceutical Design; 8(11): 1013-19, 2002.

3 F.Perrone, E.De Maio, P.Maione, M.Di Maio, A.Ottaiano, M.Pensabene, G.Di Lorenzo, A.Vernaglia Lombardi, C.Gallo. Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer. Journal of Clinical Oncology 20: 52-57, 2002.

2 Ottaiano A, Barletta E, Maione P, Fiore F, Pisano C, Di Maio M, VR Iaffaioli, C Gridelli. Pancreatic involvement from heavily pretreated small cell lung cancer successfully treated with transcatheter intraarterial chemotherapy. A case report with local and systemic disease control. Tumori 88:535-537, 2002

1 C.Gridelli and M.Di Maio. Indication for venous ports in oncology. Comparing different experiences in Europe. Tumori, 87: S69-S70, 2001.

Projects

Memberships

Other Relevant Information